Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 101
Filtrer
1.
J Mycol Med ; 34(3): 101490, 2024 Jun 04.
Article de Anglais | MEDLINE | ID: mdl-38852225

RÉSUMÉ

Due to large outbreaks observed worldwide, Candida auris has emerged as a major threat to healthcare facilities. To prevent these phenomena, a systematic screening should be performed in patients transferred from regions where the pathogen is highly endemic. In this study, we recorded and analyzed French mycologists' current knowledge and practice regarding C. auris screening and diagnosis. Thirty-six centers answered an online questionnaire. Only 11 (30.6 %) participants were aware of any systematic screening for C. auris for patients admitted to their hospital. In the case of post-admission screening, axillae/groins (n = 21), nares (n = 7), rectum (n = 9), and mouth (n = 6) alone or various combinations were the body sites the most frequently sampled. Only six centers (8.3 %) reported using a commercially available plate allowing the differentiation of C. auris colonies from that of other Candida species, while five laboratories (13.8 %) had implemented a C. auris-specific qPCR. Considering the potential impact on infected patients and the risk of disorganization in the care of patients, it is crucial to remember to biologists and clinicians the utmost importance of systematic screening on admission.

2.
Rev Mal Respir ; 41(4): 283-288, 2024 Apr.
Article de Français | MEDLINE | ID: mdl-38458868

RÉSUMÉ

Aspergillus fumigatus is the predominant fungal species causing pulmonary aspergillosis. The present-day anti-aspergillosis arsenal is limited, with a number of molecules occasioning severe side effects (amphotericin B) or provoking significant drug interactions (azole derivatives). Moreover, the recent emergence of azole-resistant A. fumigatus strains is a cause for concern. In this context, antimicrobial peptides (AMPs) are emerging as a promising therapeutic approach and alternative or complement to conventional antifungals.


Sujet(s)
Peptides antimicrobiens , Aspergillose , Humains , Résistance des champignons aux médicaments , Aspergillose/traitement médicamenteux , Aspergillose/microbiologie , Antifongiques/usage thérapeutique , Azoles/usage thérapeutique , Tests de sensibilité microbienne
3.
Sci Rep ; 12(1): 16445, 2022 09 30.
Article de Anglais | MEDLINE | ID: mdl-36180590

RÉSUMÉ

This study aimed to evaluate the contribution of Machine Learning (ML) approach in the interpretation of intercalating dye-based quantitative PCR (IDqPCR) signals applied to the diagnosis of mucormycosis. The ML-based classification approach was applied to 734 results of IDqPCR categorized as positive (n = 74) or negative (n = 660) for mucormycosis after combining "visual reading" of the amplification and denaturation curves with clinical, radiological and microbiological criteria. Fourteen features were calculated to characterize the curves and injected in several pipelines including four ML-algorithms. An initial subset (n = 345) was used for the conception of classifiers. The classifier predictions were combined with majority voting to estimate performances of 48 meta-classifiers on an external dataset (n = 389). The visual reading returned 57 (7.7%), 568 (77.4%) and 109 (14.8%) positive, negative and doubtful results respectively. The Kappa coefficients of all the meta-classifiers were greater than 0.83 for the classification of IDqPCR results on the external dataset. Among these meta-classifiers, 6 exhibited Kappa coefficients at 1. The proposed ML-based approach allows a rigorous interpretation of IDqPCR curves, making the diagnosis of mucormycosis available for non-specialists in molecular diagnosis. A free online application was developed to classify IDqPCR from the raw data of the thermal cycler output ( http://gepamy-sat.asso.st/ ).


Sujet(s)
Mucormycose , Algorithmes , Humains , Apprentissage machine , Réaction de polymérisation en chaîne
4.
Antimicrob Agents Chemother ; 64(12)2020 11 17.
Article de Anglais | MEDLINE | ID: mdl-32900686

RÉSUMÉ

The antifungal susceptibility of Aspergillus cryptic species is poorly known. We assessed 51 isolates, belonging to seven Fumigati cryptic species, by the EUCAST reference method and the concentration gradient strip (CGS) method. Species-specific patterns were observed, with high MICs for azole drugs, except for Aspergillus hiratsukae and Aspergillus tsurutae, and high MICs for amphotericin B for Aspergillus lentulus and Aspergillus udagawae Essential and categorical agreements between EUCAST and CGS results were between 53.3 and 93.3%.


Sujet(s)
Antifongiques , Aspergillus , Antifongiques/pharmacologie , Aspergillus/effets des médicaments et des substances chimiques , Tests de sensibilité microbienne
5.
J Mycol Med ; 30(2): 100970, 2020 Jun.
Article de Anglais | MEDLINE | ID: mdl-32334948

RÉSUMÉ

A survey of mycology laboratories for antifungal susceptibility testing (AFST) was undertaken in France in 2018, to better understand the difference in practices between the participating centers and to identify the difficulties they may encounter as well as eventual gaps with published standards and guidelines. The survey captured information from 45 mycology laboratories in France on how they perform AFST (number of strains tested, preferred method, technical and quality aspects, interpretation of the MIC values, reading and interpretation difficulties). Results indicated that 86% of respondents used Etest as AFST method, with a combination of one to seven antifungal agents tested. Most of the participating laboratories used similar technical parameters to perform their AFST method and a large majority used, as recommended, internal and external quality assessments. Almost all the participating mycology laboratories (98%) reported difficulties to interpret the MIC values, especially when no clinical breakpoints are available. The survey highlighted that the current AFST practices in France need homogenization, particularly for MIC reading and interpretation.


Sujet(s)
Antifongiques/usage thérapeutique , Laboratoires , Tests de sensibilité microbienne , Mycologie , Pratique professionnelle/statistiques et données numériques , Tests d'agents antimicrobiens par diffusion à partir de disques/méthodes , Tests d'agents antimicrobiens par diffusion à partir de disques/normes , Tests d'agents antimicrobiens par diffusion à partir de disques/statistiques et données numériques , Résistance des champignons aux médicaments , France , Histoire du 21ème siècle , Humains , Laboratoires/normes , Laboratoires/statistiques et données numériques , Évaluation de la compétence des laboratoires/méthodes , Évaluation de la compétence des laboratoires/statistiques et données numériques , Tests de sensibilité microbienne/méthodes , Tests de sensibilité microbienne/normes , Tests de sensibilité microbienne/statistiques et données numériques , Mycologie/histoire , Mycologie/méthodes , Mycologie/normes , Mycologie/statistiques et données numériques , Pratique professionnelle/normes , Contrôle de qualité , Enquêtes et questionnaires
6.
Article de Anglais | MEDLINE | ID: mdl-31844011

RÉSUMÉ

Reference methods used to assess the drug susceptibilities of Aspergillus fumigatus isolates consisted of EUCAST and CLSI standardized broth microdilution techniques. Considering the increasing rate and the potential impact on the clinical outcome of azole resistance in A. fumigatus, more suitable techniques for routine testing are needed. The gradient concentration strip (GCS) method has been favorably evaluated for yeast testing. The aim of this study was to compare the CGS test with EUCAST broth microdilution for amphotericin B (AMB), posaconazole (PCZ), itraconazole (ITZ), voriconazole (VRZ), and isavuconazole (ISA). A total of 121 Aspergillus section Fumigati strains were collected, including 24 A. fumigatus sensu stricto strains that were resistant to at least one azole drug. MICs were determined using GCS and EUCAST methods. Essential agreement between the 2 methods was considered when MICs fell within ±1 dilution or ±2 dilutions of the 2-fold dilution scale. Categorical agreement was defined as the percentage of strains classified in the same category (susceptible, intermediate, or resistant) with both methods. Essential agreements with ±1 dilution and ±2 dilutions were 96.7, 93.4, 90.0, 89.3, and 95% and 100, 99.2, 100, 97.5, and 100% for AMB, PCZ, ITZ, VRZ, and ISA, respectively. Categorical agreements were 94.3, 86.1, 89.3, and 88.5% for AMB, PCZ, ITZ, and VRZ, respectively. Detection of resistance was missed with the GCS for one strain (4.1%) for PCZ and for 2 strains (8.3%) for ISA. Determination of ITZ MICs using the GCS allowed the detection of 91.7% of azole-resistant strains. The GCS test appears to be a valuable method for screening azole-resistant A. fumigatus clinical isolates.


Sujet(s)
Amphotéricine B/pharmacologie , Antifongiques/pharmacologie , Azoles/pharmacologie , Aspergillus/effets des médicaments et des substances chimiques , Aspergillus/génétique , Aspergillus fumigatus/effets des médicaments et des substances chimiques , Aspergillus fumigatus/génétique , Résistance des champignons aux médicaments/génétique , Protéines fongiques/génétique , Itraconazole/pharmacologie , Tests de sensibilité microbienne , Nitriles/pharmacologie , Pyridines/pharmacologie , Triazoles/pharmacologie , Voriconazole/pharmacologie
7.
Article de Anglais | MEDLINE | ID: mdl-31767726

RÉSUMÉ

To evaluate the in vitro susceptibility of Fusarium to isavuconazole, 75 clinical isolates were identified using matrix-assisted laser desorption ionization-time of flight mass spectrometry and then tested with a broth microdilution method (EUCAST) and the gradient concentration strip (GCS) technique. The activity of isavuconazole overall was shown to be limited, with an MIC50 of >16 µg/ml, without significant differences between the species complexes. The categorical agreement between GCS and EUCAST was 97.4% to 100%, making the GCS as a valuable alternative.


Sujet(s)
Antifongiques/pharmacologie , Fusarium/effets des médicaments et des substances chimiques , Nitriles/pharmacologie , Pyridines/pharmacologie , Triazoles/pharmacologie , Fusariose/microbiologie , Tests de sensibilité microbienne
8.
Article de Anglais | MEDLINE | ID: mdl-29439956

RÉSUMÉ

Aspergillus section Terrei is a species complex currently comprised of 14 cryptic species whose prevalence in clinical samples as well as antifungal susceptibility are poorly known. The aims of this study were to investigate A. Terrei clinical isolates at the species level and to perform antifungal susceptibility analyses by reference and commercial methods. Eighty-two clinical A. Terrei isolates were collected from 8 French university hospitals. Molecular identification was performed by sequencing parts of beta-tubulin and calmodulin genes. MICs or minimum effective concentrations (MECs) were determined for 8 antifungal drugs using both EUCAST broth microdilution (BMD) methods and concentration gradient strips (CGS). Among the 79 A. Terrei isolates, A. terreus stricto sensu (n = 61), A. citrinoterreus (n = 13), A. hortai (n = 3), and A. alabamensis (n = 2) were identified. All strains had MICs of ≥1 mg/liter for amphotericin B, except for two isolates (both A. hortai) that had MICs of 0.25 mg/liter. Four A. terreus isolates were resistant to at least one azole drug, including one with pan-azole resistance, yet no mutation in the CYP51A gene was found. All strains had low MECs for the three echinocandins. The essential agreements (EAs) between BMD and CGS were >90%, except for those of amphotericin B (79.7%) and itraconazole (73.4%). Isolates belonging to the A section Terrei identified in clinical samples show wider species diversity beyond the known A. terreus sensu stricto Azole resistance inside the section Terrei is uncommon and is not related to CYP51A mutations here. Finally, CGS is an interesting alternative for routine antifungal susceptibility testing.


Sujet(s)
Antifongiques/pharmacologie , Aspergillus/effets des médicaments et des substances chimiques , Aspergillus/génétique , Amphotéricine B/pharmacologie , Azoles/pharmacologie , Échinocandines/pharmacologie , Humains , Itraconazole/pharmacologie , Tests de sensibilité microbienne
9.
J Infect ; 76(5): 483-488, 2018 05.
Article de Anglais | MEDLINE | ID: mdl-29432826

RÉSUMÉ

OBJECTIVES: Definitive diagnosis of invasive candidiasis (IC) may be difficult to achieve in patients with haematological malignancy (PHM). We aimed to evaluate the performance of BDG for the diagnosis and the follow-up of IC in PHM. PATIENTS AND METHODS: We retrospectively reviewed the serological data of BDG assay in adult and paediatric PHM, who developed candidemia or chronic disseminated candidiasis (CDC) through a 4-year period. Sensitivity and kinetics of BDG were determined for both clinical forms. RESULTS: In a panel of 3027 PHM, incidence rates of candidemia and CDC ranged between 0.74 and 0.77 and 0.30 and 0.44 according to the group of patients. At the time of diagnosis, 43.5% and 73% of cases of candidemia and CDC had a positive BDG assay, respectively. We found a significant correlation between the level of BDG at diagnosis and the outcome of candidemia (p = 0.022). In all cases of CDC, BDG negative results were obtained 2 to 6 months before recovery of the CT-scan lesions. CONCLUSIONS: BDG exhibits a low sensitivity to detect IC in PHM, but its kinetics correlates the clinical outcome. Additional studies are warranted in patients with CDC to evaluate the interest of monitoring BDG levels to anticipate the discontinuation of antifungal maintenance therapy.


Sujet(s)
Candidémie/diagnostic , Candidose invasive/diagnostic , Candidose/diagnostic , Tumeurs hématologiques/microbiologie , bêta-Glucanes/sang , Sujet âgé , Anticorps antifongiques , Antifongiques/usage thérapeutique , Candida , Candidémie/traitement médicamenteux , Candidose/traitement médicamenteux , Candidose invasive/traitement médicamenteux , Études de suivi , Humains , Unités de soins intensifs , Cinétique , Adulte d'âge moyen , Études rétrospectives , Sensibilité et spécificité
10.
Med Mycol ; 56(6): 774-777, 2018 Aug 01.
Article de Anglais | MEDLINE | ID: mdl-29087508

RÉSUMÉ

Cryptococcal antigen (CryAg) testing in serum and CSF is a clue diagnostic tool for cryptococcosis. In this study, we reviewed the performances of the CryAg detection (Premier EIA, Meridian) routinely performed in broncho-alveolar lavage fluid (BALF) during a 7-year period (2007-2013). CryAg was detected in 12 cases among 4650 BALF analyzed, while positive culture from BALF was detected in nine cases. We found sensitivity, specificity, positive and negative predictive values at 0.44-0.80 (according to the radio-clinical form), 0.99, 0.36, and 0.99, respectively. These results do not support the routine use of the test in BALF.


Sujet(s)
Liquide de lavage bronchoalvéolaire/microbiologie , Cryptococcose/diagnostic , Cryptococcus neoformans/immunologie , Antigènes fongiques/analyse , Cryptococcose/immunologie , Cryptococcose/microbiologie , Cryptococcus neoformans/isolement et purification , Bases de données factuelles , Humains , Tests au latex , Valeur prédictive des tests
11.
Antimicrob Agents Chemother ; 60(8): 5088-91, 2016 08.
Article de Anglais | MEDLINE | ID: mdl-27297480

RÉSUMÉ

In vitro susceptibility of 933 Candida isolates, from 16 French hospitals, to micafungin was determined using the Etest in each center. All isolates were then sent to a single center for determination of MICs by the EUCAST reference method. Overall essential agreement between the two tests was 98.5% at ±2 log2 dilutions and 90.2% at ±1 log2 dilutions. Categorical agreement was 98.2%. The Etest is a valuable alternative to EUCAST for the routine determination of micafungin MICs in medical mycology laboratories.


Sujet(s)
Antifongiques/pharmacologie , Candida/effets des médicaments et des substances chimiques , Échinocandines/pharmacologie , Lipopeptides/pharmacologie , Candida/génétique , Résistance des champignons aux médicaments/génétique , Micafungine , Tests de sensibilité microbienne
12.
FEMS Yeast Res ; 16(2): fov114, 2016 Mar.
Article de Anglais | MEDLINE | ID: mdl-26691882

RÉSUMÉ

During the previous decades, as the number of immunocompromised patients, the average age of Western populations and the widespread use of indwelling medical devices have increased concomitantly, so has the incidence of infections caused by Candida species. Candida albicans remains the most frequently isolated agent of candidiasis. However, C. glabrata now accounts for a substantial part of clinical isolates, ranking number two among the etiologic agents of either superficial or invasive candidiasis in North America and Europe. Along with C. glabrata and belonging to the Nakaseomyces clade, two new species, C. nivariensis and C bracarensis have recently been described as emerging pathogens. This review provides information on the current state of knowledge on the epidemiology, biology, identification, pathogenicity and antifungal resistance of C. glabrata, C. nivariensis and C. bracarensis.


Sujet(s)
Antifongiques/pharmacologie , Candida/classification , Candida/isolement et purification , Candidose/épidémiologie , Candidose/microbiologie , Résistance des champignons aux médicaments , Candida/effets des médicaments et des substances chimiques , Candida/physiologie , Maladies transmissibles émergentes/épidémiologie , Maladies transmissibles émergentes/microbiologie , Santé mondiale , Humains , Facteurs de virulence/génétique
13.
J Clin Microbiol ; 53(12): 3870-5, 2015 Dec.
Article de Anglais | MEDLINE | ID: mdl-26468505

RÉSUMÉ

Quantitative PCR (qPCR) is now a key diagnostic tool for Pneumocystis pneumonia. However, cutoffs to distinguish between infected and colonized patients according to their HIV status have not yet been determined. According to clinical, radiological, and biological data, we retrospectively classified bronchoalveolar lavage (BAL) samples subjected to qPCR over a 3-year period into four categories, i.e., definite PCP, probable PCP, Pneumocystis colonization, and no infection. Fungal burden was then analyzed according to the HIV status of the patients. Among 1,212 episodes of pneumonia screened in immunocompromised patients, 52 and 27 HIV-positive patients were diagnosed with a definite and probable PCP, whereas 4 and 22 HIV-negative patients had definite and probable PCP, respectively. Among patients with definite or a probable PCP, HIV-negative patients had a significantly lower burden than HIV-positive patients (P < 10(-4)). In both groups, the median fungal burden was significantly higher in patients with definite PCP than in colonized patients. A single cutoff at 1.5 × 10(4) copies/ml allowed to differentiate colonized and infected HIV-positive patients with 100% sensitivity and specificity. In HIV-negative patients, cutoff values of 2.87 × 10(4) and 3.39 × 10(3) copies/ml resulted in 100% specificity and sensitivity, respectively. Using cutoffs determined for the whole population would have led us to set aside the diagnosis of PCP in 9 HIV-negative patients with definite or probable PCP. qPCR appeared to be the most sensitive test to detect Pneumocystis in BAL samples. However, because of lower inocula in HIV-negative patients, different cutoffs must be used according to the HIV status to differentiate between colonized and infected patients.


Sujet(s)
État de porteur sain/diagnostic , Numération de colonies microbiennes/méthodes , Infections à VIH/complications , Pneumocystis carinii/isolement et purification , Pneumonie à Pneumocystis/diagnostic , Réaction de polymérisation en chaine en temps réel/méthodes , Adulte , Sujet âgé , Liquide de lavage bronchoalvéolaire/microbiologie , État de porteur sain/microbiologie , Femelle , Humains , Mâle , Adulte d'âge moyen , Pneumonie à Pneumocystis/microbiologie , Études rétrospectives
14.
J Clin Microbiol ; 53(5): 1655-61, 2015 May.
Article de Anglais | MEDLINE | ID: mdl-25762773

RÉSUMÉ

Candida inconspicua and Candida (Pichia) norvegensis are two emerging pathogenic species that exhibit reduced susceptibility to azole derivatives. Conventional (biochemical) approaches do not readily differentiate between the two species. The first aim of this work was to analyze the performance of biochemical, proteomic (matrix-assisted laser desorption ionization-time of flight [MALDI-TOF]), and molecular approaches in the precise identification of these species. These results then led us to sequence 3 genomic loci, i.e., the internal transcribed spacer (ITS) region of the ribosomal DNA (rDNA), the D1/D2 domain of the 28S rDNA, and the elongation factor 1α (EF-1α) gene, either directly or following cloning, of 13 clinical isolates and 9 reference strains belonging to the 5 species included in the Pichia cactophila clade, namely, Pichia cactophila, Pichia insulana, C. inconspicua, C. norvegensis, and P. pseudocactophila. Finally, isolates of C. inconspicua were challenged for sexual reproduction on the appropriate medium. Our results show that EF-1α sequencing and proteic profiling by MALDI-TOF are the two most efficient approaches to distinguish between C. norvegensis and C. inconspicua. As a characteristic of the P. cactophila clade, we found multiple alleles of the rDNA regions in certain strains belonging to the tested species, making ITS or D1/D2 sequencing not appropriate for identification. Whatever the method of identification, including MALDI-TOF and EF-1α sequencing, none could differentiate C. inconspicua from P. cactophila. The results of phylogenetic analysis and the generation of asci from pure cultures of all C. inconspicua strains both support the identification of P. cactophila as the teleomorph of C. inconspicua.


Sujet(s)
Candida/classification , Croisements génétiques , Ordre des gènes , Candida/composition chimique , Candida/génétique , Candida/métabolisme , Candidose/microbiologie , Analyse de regroupements , ADN fongique/composition chimique , ADN fongique/génétique , ADN ribosomique/composition chimique , ADN ribosomique/génétique , Espaceur de l'ADN ribosomique/composition chimique , Espaceur de l'ADN ribosomique/génétique , Humains , Données de séquences moléculaires , Techniques de typage mycologique , Facteur-1 d'élongation de la chaîne peptidique/génétique , Phylogenèse , Protéome/analyse , ARN ribosomique 28S/génétique , Analyse de séquence d'ADN , Spectrométrie de masse MALDI
15.
J Mycol Med ; 25(1): 87-90, 2015 Mar.
Article de Anglais | MEDLINE | ID: mdl-25649231

RÉSUMÉ

Candiduria may be a marker of serious fungal infections such as pyelonephritis. With the exception of fluconazole and flucytosine, antifungals drugs are not excreted into the urine as active drugs, making the management of infection due to fluconazole-resistant Candida difficult. We report a case of recurrent Candida parapsilosis candiduria in a kidney transplant recipient suffering from chronic ureteral obstruction requiring permanent ureteral catheterization (double-J stent). Attempts to remove the stent led to pyelonephritis episodes during which only Candida was isolated from the urine. Following several courses of azole-based therapy, the causative agent became resistant to fluconazole. Clinical and mycological cure were obtained combining irrigations of caspofungin through a percutaneous calicostomy catheter and oral flucytosine. This strategy may represent an interesting therapeutic alternative in case of fluconazole-resistant symptomatic candiduria.


Sujet(s)
Candidose invasive/thérapie , Échinocandines/administration et posologie , Flucytosine/administration et posologie , Calices rénaux/chirurgie , Infections urinaires/thérapie , Administration par voie orale , Adulte , Antifongiques/administration et posologie , Antifongiques/usage thérapeutique , Candidose invasive/urine , Caspofungine , Association thérapeutique , Résistance des champignons aux médicaments , Fluconazole/usage thérapeutique , Humains , Calices rénaux/anatomopathologie , Lipopeptides , Mâle , Irrigation thérapeutique/méthodes , Cathétérisme urinaire/méthodes
16.
Am J Transplant ; 14(4): 867-75, 2014 Apr.
Article de Anglais | MEDLINE | ID: mdl-24580771

RÉSUMÉ

Although large retrospective studies have identified the presence of donor-specific antibodies (DSAs) to be a risk factor for rejection and impaired survival after liver transplantation, the long-term predicted pathogenic potential of individual DSAs after liver transplantation remains unclear. We investigated the incidence, prevalence and consequences of DSAs in maintenance liver transplant (LT) recipients. Two hundred sixty-seven LT recipients, who had undergone transplantation at least 6 months previously and had been screened for DSAs at least twice using single-antigen bead technology, were included and tested annually for the presence of DSAs. At a median of 51 months (min-max: 6-220) after an LT, 13% of patients had DSAs. At a median of 36.5 months (min-max: 2-45) after the first screening, 9% of patients have developed de novo DSAs. The sole predictive factor for the emergence of de novo DSAs was retransplantation (OR 3.75; 95% CI 1.28-11.05, p = 0.025). Five out of 21 patients with de novo DSAs (23.8%) developed an antibody-mediated rejection. Fibrosis score was higher among patients with DSAs. In conclusion, monitoring for the development of DSAs in maintenance LT patients is useful in case of graft dysfunction and to identify patients with a high risk of developing liver fibrosis.


Sujet(s)
Rejet du greffon/étiologie , Antigènes HLA/sang , Alloanticorps/sang , Cirrhose du foie/étiologie , Maladies du foie/chirurgie , Transplantation hépatique/effets indésirables , Adolescent , Adulte , Sujet âgé , Femelle , Études de suivi , Rejet du greffon/épidémiologie , Rejet du greffon/mortalité , Survie du greffon , Antigènes HLA/immunologie , Humains , Incidence , Alloanticorps/immunologie , Cirrhose du foie/épidémiologie , Cirrhose du foie/mortalité , Maladies du foie/complications , Maladies du foie/mortalité , Mâle , Adulte d'âge moyen , Prévalence , Pronostic , Études prospectives , Réintervention , Études rétrospectives , Facteurs de risque , Taux de survie , Jeune adulte
17.
Transpl Infect Dis ; 16(1): 135-40, 2014 Feb.
Article de Anglais | MEDLINE | ID: mdl-24383613

RÉSUMÉ

Trichosporon species are rare etiologic agents of invasive fungal infection in solid organ transplant (SOT) recipients. We report 2 well-documented cases of Trichosporon inkin invasive infection in SOT patients. We also conducted a detailed literature review of Trichosporon species infections in this susceptible population. We gathered a total of 13 cases of Trichosporon species infections. Any type of organ transplantation can be complicated by Trichosporon infection. Bloodstream infections and disseminated infections were the most common clinical presentations. Liver recipients with bloodstream or disseminated infections had poor prognoses. Although the most common species was formerly called Trichosporon beigelii, this species name should no longer be used because of the changes in the taxonomy of this genus resulting from the advent of molecular approaches, which were also used to identify the strains isolated from our patients. Antifungal susceptibility testing highlights the possibility of multidrug resistance. Indeed, Trichosporon has to be considered in cases of breakthrough infection or treatment failure under echinocandins or amphotericin therapy. Voriconazole seems to be the best treatment option.


Sujet(s)
ADN fongique/analyse , Empyème/immunologie , Rejet du greffon/prévention et contrôle , Transplantation cardiaque , Sujet immunodéprimé , Immunosuppresseurs/usage thérapeutique , Mycoses pulmonaires/immunologie , Transplantation pulmonaire , Médiastinite/immunologie , Péricardite/immunologie , Trichosporon/génétique , Trichosporonose/immunologie , Adulte , Antifongiques/usage thérapeutique , ADN intergénique/analyse , ADN ribosomique/analyse , Résistance des champignons aux médicaments , Empyème/diagnostic , Empyème/traitement médicamenteux , Humains , Mycoses pulmonaires/diagnostic , Mycoses pulmonaires/traitement médicamenteux , Mâle , Médiastinite/diagnostic , Médiastinite/traitement médicamenteux , Tests de sensibilité microbienne , Péricardite/diagnostic , Péricardite/traitement médicamenteux , Épanchement pleural/diagnostic , Épanchement pleural/traitement médicamenteux , Épanchement pleural/immunologie , Pyrimidines/usage thérapeutique , Analyse de séquence d'ADN , Triazoles/usage thérapeutique , Trichosporonose/diagnostic , Trichosporonose/traitement médicamenteux , Voriconazole , Jeune adulte
18.
Clin Microbiol Infect ; 20(2): 153-8, 2014 Feb.
Article de Anglais | MEDLINE | ID: mdl-23594150

RÉSUMÉ

Candida spp. are responsible for severe infections in immunocompromised patients and those undergoing invasive procedures. The accurate identification of Candida species is important because emerging species can be associated with various antifungal susceptibility spectra. Conventional methods have been developed to identify the most common pathogens, but have often failed to identify uncommon species. Several studies have reported the efficiency of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) for the identification of clinically relevant Candida species. In this study, we evaluated two commercially available MALDI-TOF systems, Andromas™ and Bruker Biotyper™, for Candida identification in routine diagnosis. For this purpose, we investigated 1383 Candida isolates prospectively collected in eight hospital laboratories during routine practice. MALDI-TOF MS results were compared with those obtained using conventional phenotypic methods. Analysis of rDNA gene sequences with internal transcribed regions or D1-D2 regions is considered the reference standard for identification. Both MALDI-TOF MS systems could accurately identify 98.3% of the isolates at the species level (1359/1383 for Andromas™; 1360/1383 for Bruker Biotyper™) vs. 96.5% for conventional techniques. Furthermore, whereas conventional methods failed to identify rare or emerging species, these were correctly identified by MALDI-TOF MS. Both MALDI-TOF MS systems are accurate and cost-effective alternatives to conventional methods for mycological identification of clinically relevant Candida species and should improve the diagnosis of fungal infections as well as patient management.


Sujet(s)
Candida/classification , Candida/isolement et purification , Techniques microbiologiques/méthodes , Spectrométrie de masse MALDI/méthodes , Candida/composition chimique , Candidose/diagnostic , Candidose/microbiologie , Humains , Études prospectives
20.
Clin Microbiol Infect ; 20(8): 784-90, 2014 Aug.
Article de Anglais | MEDLINE | ID: mdl-24355037

RÉSUMÉ

Trichosporon spp. have recently emerged as significant human pathogens. Identification of these species is important, both for epidemiological purposes and for therapeutic management, but conventional identification based on biochemical traits is hindered by the lack of updates to the species databases provided by the different commercial systems. In this study, 93 strains, or isolates, belonging to 16 Trichosporon species were subjected to both molecular identification using IGS1 gene sequencing and matrix-assisted laser desorption ionisation-time-of-flight (MALDI-TOF) analysis. Our results confirmed the limits of biochemical systems for identifying Trichosporon species, because only 27 (36%) of the isolates were correctly identified using them. Different protein extraction procedures were evaluated, revealing that incubation for 30 min with 70% formic acid yields the spectra with the highest scores. Among the six different reference spectra databases that were tested, a specific one composed of 18 reference strains plus seven clinical isolates allowed the correct identification of 67 of the 68 clinical isolates (98.5%). Although until recently it has been less widely applied to the basidiomycetous fungi, MALDI-TOF appears to be a valuable tool for identifying clinical Trichosporon isolates at the species level.


Sujet(s)
Spectrométrie de masse MALDI/méthodes , Trichosporon/composition chimique , Trichosporon/classification , Trichosporonose/diagnostic , Trichosporonose/microbiologie , Protéines fongiques/composition chimique , Protéines fongiques/isolement et purification , Humains , Sensibilité et spécificité , Manipulation d'échantillons/méthodes , Trichosporon/isolement et purification
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...